EBIT at other companies
Other financials
Where this comes from
Calculated from NewAmsterdam Pharma Company’s reported figures.
Plus components not separately reported this period.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's EBIT?
- NewAmsterdam Pharma Company (NAMS) reported EBIT of -$58.42M in Q1 2026.
- How has NewAmsterdam Pharma Company's EBIT changed year-over-year?
- NewAmsterdam Pharma Company's EBIT increased by 15.2% year-over-year, from -$68.93M to -$58.42M.
- What is the long-term trend for NewAmsterdam Pharma Company's EBIT?
- Over 4 years (2021 to 2025), NewAmsterdam Pharma Company's EBIT has grown at a 59.4% compound annual growth rate (CAGR), from -$34.98M to -$225.68M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.